Working… Menu
Trial record 1 of 1 for:    ETAL3 | AML | Germany
Previous Study | Return to List | Next Study

Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML (ETAL3-ASAP)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02461537
Recruitment Status : Recruiting
First Posted : June 3, 2015
Last Update Posted : July 30, 2020
Information provided by (Responsible Party):
DKMS gemeinnützige GmbH

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : December 2022
Estimated Study Completion Date : May 2023